Results 1 to 10 of about 35,569 (305)

Insulin–glucagon‐like peptide‐1 receptor agonist relay and glucagon‐like peptide‐1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open‐label trial study

Journal of Diabetes Investigation, 2022
Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) might be less effective in patients with severe hyperglycemia, because hyperglycemia downregulated the GLP‐1 receptor in an animal study.
Yumie Takeshita, Yuki Kita, Takeo Tanaka, Hisanori Goto, Yujiro Nakano, Chisato Teramura, Yasufumi Enyama, Toshinari Takamura, the Establishment of Rationale for Antiaging Diabetic Medicine (ERA‐DM) Study Group   +8 more
doaj   +2 more sources

Association of glucagon‐like peptide‐1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy

Journal of Diabetes Investigation, 2023
Aims/Introduction Previous studies have reported that the glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) delays gastric emptying, and gastric emptying was assessed by the 13C breath test or paracetamol absorption technique.
Toshiko Kobori, Yukiko Onishi, Yoko Yoshida, Tazu Tahara, Takako Kikuchi, Tetsuya Kubota, Masahiko Iwamoto, Tomonobu Sawada, Reo Kobayashi, Hiroaki Fujiwara, Masato Kasuga   +10 more
doaj   +2 more sources

Glucagon-like peptide-1 receptor ligand interactions: structural cross talk between ligands and the extracellular domain. [PDF]

PLoS ONE, 2014
Activation of the glucagon-like peptide-1 receptor (GLP-1R) in pancreatic β-cells potentiates insulin production and is a current therapeutic target for the treatment of type 2 diabetes mellitus (T2DM).
Graham M West, Francis S Willard, Kyle W Sloop, Aaron D Showalter, Bruce D Pascal, Patrick R Griffin   +5 more
doaj   +2 more sources

Glucagon-like peptide-1 receptor agonists in neoplastic diseases [PDF]

Frontiers in Endocrinology
Glucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing weight, and lowering blood lipids. It has also been shown that it can influence the proliferation and survival of cells and has a certain effect on ...
Lisan Ji, Xianzhen He, Xinwen Min, Handong Yang, Wenwen Wu, Hao Xu, Jun Chen, Jun Chen, Aihua Mei   +8 more
openaire   +4 more sources

Patient preferences for glucagon-like peptide-1 receptor–agonist treatment attributes

Patient Preference and Adherence, 2019
Vivian T Thieu,1 Susan Robinson,2 Tessa Kennedy-Martin,2 Kristina S Boye,1 Luis-Emilio Garcia-Perez1 1Global Patient Outcomes and Real-World Evidence, Eli Lilly and Company, Indianapolis, IN, USA; 2Kennedy-Martin Health Outcomes (KMHO), Brighton, UK ...
Thieu VT, Robinson S, Kennedy-Martin T, Boye KS, Garcia-Perez LE   +4 more
doaj   +1 more source

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes [PDF]

Annals of Pediatric Endocrinology & Metabolism, 2017
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary ...
Seungah Lee, Dong Yun Lee
doaj   +3 more sources

Suspected liraglutide (glucagon-like peptide-1 receptor agonist)-induced hyperthyroidism: A case report [PDF]

Malaysian Family Physician
Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), is widely used for weight management and glycaemic control. While generally well-tolerated, various adverse effects have been reported. Thyroid dysfunction, particularly hyperthyroidism,
Siti Nur Syakinah Md Sabudin, Lili Husniati Yaacob, Muhammad Rahmat Che Omar   +2 more
doaj   +2 more sources

Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis

Frontiers in Endocrinology, 2021
ObjectiveNon-alcoholic fatty liver disease is highly prevalent in patients with type 2 diabetes mellitus. Studies on glucagon-like peptide-1 receptor agonists for the treatment of non-alcoholic fatty liver disease have reported promising results. Despite
Chloe Wong, Ming Hui Lee, Clyve Yu Leon Yaow, Yip Han Chin, Xin Lei Goh, Cheng Han Ng, Amanda Yuan Ling Lim, Amanda Yuan Ling Lim, Mark Dhinesh Muthiah, Mark Dhinesh Muthiah, Mark Dhinesh Muthiah, Chin Meng Khoo, Chin Meng Khoo   +12 more
doaj   +1 more source

Systemic GLP-1R agonist treatment reverses mouse glial and neurovascular cell transcriptomic aging signatures in a genome-wide manner

Communications Biology, 2021
Li, Chen, Vong, Zhao et al. show that glucagon-like peptide-1 receptor agonist reverses transcriptomic aging signatures in mouse glial and neurovascular cells.
Zhongqi Li, Xinyi Chen, Joaquim S. L. Vong, Lei Zhao, Junzhe Huang, Leo Y. C. Yan, Bonaventure Ip, Yun Kwok Wing, Hei-Ming Lai, Vincent C. T. Mok, Ho Ko   +10 more
doaj   +1 more source

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects

Journal of Diabetes Investigation, 2020
Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are used for treatment of type 2 diabetes mellitus worldwide. However, some patients do not respond well to the therapy, and caution must be taken for certain patients, including those
Takaaki Murakami, Hiroyuki Fujimoto, Naotaka Fujita, Keita Hamamatsu, Daisuke Yabe, Nobuya Inagaki   +5 more
doaj   +1 more source